Asia Pacific bioprocess technology market will grow by 15.0% annually with a total addressable market cap of $170.71 billion over 2024-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology sector, ongoing technological advancements, and a rising number of new drug production and launches.
Highlighted with 36 tables and 60 figures, this 133-page report “Asia Pacific Bioprocess Technology Market 2023-2033 by Product (Instruments, Consumables and Accessories), Process (Upstream, Downstream), Procedure, Application (Recombinant Proteins, Antibiotics, Biosimilars, mAbs, Others), End User (Biopharma Companies, CMOs, Institutes, CROs), and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire Asia Pacific bioprocess technology market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Fiver Forces


The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific bioprocess technology market in every aspect of the classification from perspectives of Product, Process, Procedure, Application, End User, and Country.

Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.

  • Instruments


o Bioprocess Analyzers
o Osmometers
o Bioreactors
o Incubators
o Other Instruments

  • Consumables and Accessories


o Culture Media
o Reagents
o Other Consumables and Accessories

Based on Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.

  • Upstream Bioprocessing
  • Downstream Bioprocessing



By Procedure, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.

  • Cell Culture
  • Cell Expansion
  • Flow Cytometry
  • Cell Line Development
  • Cell Counting
  • Biologics Safety Testing
  • Tangential Flow Filtration (TFF)
  • Other Procedures



By Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.

  • Recombinant Proteins
  • Antibiotics
  • Biosimilars
  • Monoclonal Antibodies (mAbs)
  • Other Applications



By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.

  • Biopharmaceutical Companies
  • Contract Manufacturing Organizations (CMOs)
  • Academic Research Institutes
  • Contract Research Organizations (CROs)
  • Food & Feed Industry
  • Other End Users



Geographically, the following national/local markets are fully investigated:

  • Japan
  • China
  • South Korea
  • Australia
  • India
  • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)


For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2023-2033. The breakdown of national markets by Product, Application, and End User over the forecast years are also included.

The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Advanced Instruments LLC
Agilent Technologies, Inc.
Becton Dickinson and Company
Bio-rad Laboratories Inc.
Boehringer Ingelheim International GmbH
Catalent Inc.
Charles River Laboratories
Corning Inc.
Danaher Corporation
Elitechgroup Inc. (gonotec Gmbh)
Eppendorf Se
F. Hoffmann-la Roche Ltd.
Fujifilm Healthcare Americas Corporation
GE Healthcare (General Electric Company)
Getinge Ab
Koninklijke Philips N.V.
Lonza Group Ag
Merck Kgaa
Repligen Corp.
Sartorius Group
STADA Arzneimittel AG
Thermo Fisher Scientific Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)